Gevokizumab ( Investigational drug (no approved brand names for cancer treatment) )

Immunotherapy

Not submitted to EMA

Not available 1 Clinical Trials

Description

Gevokizumab is an investigational immunotherapy drug currently being studied in clinical trials. It is being investigated for its potential use in treating metastatic colorectal cancer (mCRC), as well as other types of cancer like gastroesophageal and renal cell carcinoma. The goal of the trials is to find the right dose of gevokizumab and see how well it works when given alongside standard chemotherapy and other cancer treatments. It is not yet approved for treating any cancer.

Mechanism of Action

Gevokizumab is a monoclonal antibody. It targets a specific protein involved in the growth and spread of certain cancers. By blocking this protein, gevokizumab aims to help the body's immune system better recognize and attack cancer cells. The specific protein it targets is being studied in clinical trials.

Side Effects

Gevokizumab is still in early-phase clinical trials (Phase 1). Therefore The full range of potential side effects is still being evaluated. Side effects observed in early trials often include those related to the standard cancer treatments given alongside gevokizumab (like chemotherapy). Specific side effects related to gevokizumab itself are still being determined in ongoing studies.

Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.

Clinical Trials

NCT03798626 Phase 1

Completed

Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers

United States, Australia, Belgium, Canada, Chile, Czechia, Germany, Israel, Ital

Quick Info

Brand Name	Investigational drug (no approved brand names for cancer treatment)
Category	Immunotherapy
EMA Status	Not submitted to EMA
Spain Access	Not available
Clinical Trials	1

View Clinical Trials Back to Drug Glossary

Related Medications

Medical Disclaimer

This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.

Gevokizumab (** Investigational drug (no approved brand names for cancer treatment) **)